Middle East & Africa Transthyretin Amyloidosis Treatment Market Size & Outlook
Related Markets
MEA transthyretin amyloidosis treatment market highlights
- The MEA transthyretin amyloidosis treatment market generated a revenue of USD 72.7 million in 2024.
- The market is expected to grow at a CAGR of 11.2% from 2025 to 2030.
- In terms of segment, targeted therapy was the largest revenue generating therapy in 2024.
- Targeted Therapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
| Market revenue in 2024 | USD 72.7 million |
| Market revenue in 2030 | USD 157.2 million |
| Growth rate | 11.2% (CAGR from 2025 to 2030) |
| Largest segment | Targeted therapy |
| Fastest growing segment | Targeted Therapy |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Targeted Therapy, Supportive Therapy |
| Key market players worldwide | Pfizer Inc, Johnson & Johnson, Ionis Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Astellas Pharma Inc, Prothena Corp PLC, Acrotech BioPharma, SOM Biotech |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.1% of the global transthyretin amyloidosis treatment market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 8,083.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Transthyretin Amyloidosis Treatment Market Scope
Transthyretin Amyloidosis Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| SOM Biotech | View profile | 11-50 | Barcelona, Catalonia, Spain, Europe | http://www.sombiotech.com/ |
| Acrotech BioPharma | View profile | 51-100 | Windsor, New Jersey, United States, North America | https://acrotechbiopharma.com/ |
| Prothena Corp PLC | View profile | 173 | 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Ireland, D02 VK60 | https://www.prothena.com |
| Astellas Pharma Inc | View profile | 14484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | http://www.astellas.com |
| BridgeBio Pharma Inc | View profile | 556 | 3160 Porter Drive, Suite 250, Palo Alto, CA, United States, 94304 | https://www.bridgebio.com |
| Alnylam Pharmaceuticals Inc | View profile | 2100 | 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, United States, 02142 | https://www.alnylam.com |
| Ionis Pharmaceuticals Inc | View profile | 927 | 2855 Gazelle Court, Carlsbad, CA, United States, 92010 | https://www.ionispharma.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Middle East & Africa transthyretin amyloidosis treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to transthyretin amyloidosis treatment market will help companies and investors design strategic landscapes.
Targeted therapy was the largest segment with a revenue share of 113.89% in 2024. Horizon Databook has segmented the Middle East & Africa transthyretin amyloidosis treatment market based on targeted therapy, supportive therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Middle East & Africa transthyretin amyloidosis treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa transthyretin amyloidosis treatment market databook
-
Our clientele includes a mix of transthyretin amyloidosis treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa transthyretin amyloidosis treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa transthyretin amyloidosis treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA transthyretin amyloidosis treatment market size, by country, 2018-2030 (US$M)
Middle East & Africa Transthyretin Amyloidosis Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
